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Abstract: A series of new conjugated compounds with a –SCH2– linkage were synthesized by
chemical methods from imidazole and coumarin derivatives. The experimental results indicate that
of the twenty newly synthesized imidazole–coumarin conjugates, three of them exhibited appealing
EC50 values (5.1–8.4 µM) and selective indices >20 against hepatitis C virus. Their potency and
selectivity were increased substantially by modification of their structure with two factors: imidazole
nucleus with a hydrogen atom at the N(1) position and coumarin nucleus with a substituent, such as
Cl, F, Br, Me, and OMe. These guidelines provide valuable information for further development of
conjugated compounds as anti-viral agents.
Keywords: imidazole; nitrogen heterocycles; coumarin; hepatitis C virus; structure–activity
relationships
1. Introduction
Hepatitis C virus (HCV) infection afflicts ~150 million people worldwide (~3% of the global
population), with approximately 3–4 million new cases occurring annually [1]. HCV generally
causes both mild and acute liver disease, possibly leading to cirrhosis, hepatocellular carcinoma,
and liver failure. The traditional therapeutic treatment involves administering interferon α-2 or its
PEGylated form, either alone or in combination with ribavirin [2,3]. In 2011, boceprevir and telaprevir
were approved for the treatment of chronic hepatitis C genotype 1 infection in combination with
peg-interferon α and ribavirin. The recommended treatment regimens have significantly increased
the overall cure rates [4,5]. The above therapeutic treatments, however, still have substantial adverse
effects [6]. During the past two years, the U.S. Food and Drug Administration has approved Harvoni™
(ledipasvir/sofosbuvir), simeprevir, sofosbuvir, and Viekira Pak™ (ombitasvir/paritaprevir/ritonavir
tablet; dasabuvir tablet). Harvoni™ and Viekira Pak™ are combination pills in which each of the
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active ingredients therein has a distinct mechanism of action (MOA) [7,8]. As new generation drugs
for the treatment of HCV infections, the recommended 12- or 24-week courses of therapy of both are
highly expensive [9]. Thus, pharmaceutical companies are still seeking chemical entities with safer and
lower price than the existing drugs to combat the HCV disease. Our recent works introduced a series
of coumarin-containing conjugated compounds as new anti-HCV agents, including benzimidazole–,
heterobicycle–, and (ribosyl)purine–coumarin conjugates [10–14]. The aim of this work was to
synthesize new compounds with a scaffold containing a coumarin moiety that is conjugated with an
imidazole moiety or its derivatives, including (1-ribofuranosyl)imidazole, inosine, and guanosine.
Their anti-HCV activity is to be explored and their structure–activity is to be deduced.
Coumarins belong to an important family of compounds with various pharmacological
functions [15,16]. Despite the development of their derivatives as HCV NS3¨ 4A protease inhibitors
and NS5B polymerase inhibitors [15,17], the flat and shallow substrate-binding groove of proteases
inhibits their potency and selectivity [18,19].
Imidazole derivatives and imidazole-2-thiones represent a class of compounds with important
pharmacological properties, including anti-bacterial [20], anti-inflammatory [21], anti-cancer [22], and
anti-viral activities [23,24]. In the histidine moieties of enzymes, the imidazole ring functions as a
proton donor or acceptor or both in enzymic reactions in the charge-relay system when it is in a free
base form [25]. Therefore, many well-known biocatalysts possess this moiety. Several investigations
have elucidated the N-alkylation of imidazole compounds, which alter the pharmacological actions
and pharmacokinetics [26,27].
In 2010, Zai and co-workers [28] reported that inosine alters gene expression and axonal
projections in neurons contralateral to a cortical infarct. Additionally, it exerts a broad range of
anti-inflammatory effects in a murine model of acute lung injury, as found by Liaud et al. [29]. Inosine
is also the major component of the drug isoprinosine for the treatment of chronic hepatitis B. This
drug inhibits replication of many RNA and DNA viruses in vivo and in vitro [30]. It also exerts an
immunostimulatory effect by enhancing T-cell function and macrophage activity [31]. Containing
inosine as a major component, the drug Isoprinosine unfortunately exhibits several side effects [32].
Those effects include dyspepsia, hypersensitivity reactions, and severe drug reactions with ribavirin
that may result in a drop in the white blood cell count of patients.
Giuliani and co-workers [33] recognized protective activity of guanosine in an in vitro model of
Parkinson’s disease. Very recently, Gosselin et al. [34] reported a 21-C-methyl branched guanosine
pro-nucleotide as a potent liver-targeted HCV polymerase inhibitor. Schaefer–Korting et al. [35] found
that a guanosine-analog phosphonate can improve topical non-melanoma skin cancer treatment.
This work extends the range of available benzimidazole–coumarin conjugates by replacement
of the benzimidazole moiety therein with an imidazole moiety or its derivatives (i.e., inosine and
guanosine). An attempt is also made to understand how they influence the anti-HCV activity
of the conjugated compounds by use of three structural relatives, namely N-H, N-methyl, and
N-ribofuranosyl imidazoles. Additionally, various substituents (i.e., F, Cl, Br, Me, and OMe) are attached
to the coumarin moiety. In total, 20 imidazole–coumarin conjugated compounds with the common
skeleton shown in Figure 1 below were synthesized and their structure–activity relationships derived.
Figure 1. General structure of targed imidazole–coumarin conjugates.
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2. Results and Discussion
2.1. Chemistry
To investigate the effects of different moieties or functional groups attached to the core,
our research group synthesized four series of imidazole–coumarin conjugated compounds. The
corresponding synthetic procedures are described as follows.
2.1.1. Synthesis of Imidazole–Coumarin Conjugates
Conjugates with a coumarin moiety attached at the C(2)-position of the imidazole group via
a thiomethylene joint were synthesized. Correspondingly, 1H-imidazole-2-thiol (1a) was coupled
with various 3-(chloromethyl)coumarins 2 in the presence of aqueous ammonia and acetonitrile.
Conjugates 3a–e with different substituents (e.g., F, Cl, Br, and OMe) were obtained in 65%–86%
yields. Furthermore, their methyl analogs (i.e., 3f and 3g) were prepared by alkylation of
1-methylimidazole-2-thiol (1b) with coumarins 2a and 2c, respectively. Under these alkaline conditions,
the NH group of 1 did not compete with the C(2)-thiol group for nucleophilic attack of the coumarin
substrates [12] (Scheme 1).
Scheme 1. Synthesis of imidazole–coumarin conjugates.
2.1.2. Synthesis of (1-Ribofuranosyl)imidazole–Coumarin Conjugates
Nucleoside derivatives are promising candidates for anti-viral drugs [36,37], which explains our
intention to prepare (1-ribofuranosyl)imidazole–coumarin conjugates for an anti-viral activity assay.
First, silylation of 1H-imidazole-2-thiol (1a) with N,O-bis(trimethylsilyl)acetamide (BTSA) [38] gave
the intermediates, which were then coupled with 1,2,3,5-tetra-O-acetyl-β-D-ribofuranose (4) in the
presence of Me3SiOTf and acetonitrile at 80 ˝C. Subsequent removal of the three acetyl groups in 5
with K2CO3 in methanol provided the resultant thiol 6. Its coupling [39] with coumarins 2 produced
(1-ribofuranosyl)imidazole–coumarin conjugates 7 in good yields (72%–84%) (Scheme 2).
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Scheme 2. Synthesis of (1-ribofuranosyl)imidazole–coumarin conjugates.
2.1.3. Synthesis of Inosine– and Guanosine–Coumarin Conjugates
We found that the desired SN2 reactions occurred at the thiol group of compounds 8 [40] and
10 [41] with the allylic position of 3-(chloromethyl)coumarins 2 to give the desired conjugated products
9 and 11, respectively. The unwanted Michael addition did not occur at the α,β-unsaturated lactone
moiety of coumarins 2. The key factors for success involved the use of 35% aqueous ammonia and
acetonitrile as the media at room temperature. Accordingly, yields of 70%–83% for inosine–coumarins
9 and 74%–89% for guanosine–coumarins 11 were obtained (Scheme 3).
Scheme 3. Synthesis of inosine– and guanosine-coumarin conjugates.
2.1.4. Identification of the Structures of New Conjugated Compounds
The structures of all newly synthesized compounds were confirmed on the basis of their
spectroscopic characteristics. For instance, the IR spectrum of conjugates 7a displayed a strong
absorption band at 1698 cm´1 , which was contributed to the carbonyl stretching vibration of the
coumarin moiety [42]. Its 13C-NMR spectrum had resonances at 34.27 and 151.94 ppm for the
SCH2 carbon and the –N=C(–N)(–S) carbons, respectively. Furthermore, a doublet with J = 7.2 Hz
occurred at 5.67 ppm for the glycosidic proton [43] in its 1H-NMR spectrum. Nevertheless, it
was beyond our expection that the two characteristic singlets, instead of doublets, occurred at
7.49 and 6.99 ppm for the protons in the imidazole nucleus. Our data are in consistent with
those of N-(β-D-ribofuranosyl)imidazole, the parent compound of 7a, as reported by Mourabit and
co-workers [44].
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In addition, a doublet with J = 6.4 Hz at 5.76 ppm in the 1H-NMR spectrum was assigned as
the anomeric hydrogen of compound 9a. They also exhibited two characteristic doublets at 4.39
and 4.34 ppm with J = 14.2 Hz for the two SCH2 hydrogens and a singlet at 8.06 ppm for the
NH–CH=N proton in inosine moiety. In its 13C-NMR spectrum, resonance occurred at 32.04 ppm for
the SCH2 carbon.
2.2. Pharmacology
Anti-HCV Activity
The antiviral activity of conjugated compounds 3a–g, 7a–e, 9a,b,d–f, and 11b,e,f in the HCV
genotype 1b subgenomic Huh 5-2 replicon system [45] was evaluated according to established
procedures [46]. On the basis of the dose-response curves that were obtained, the concentration of a
compound that inhibited virus replication by 50% (i.e., EC50) and the concentration of compound that
reduced host cell metabolism by 50% (i.e., CC50) were obtained. These values subsequently allowed us
to calculate the selectivity index (i.e., SI = CC50/EC50), which is a measure for the therapeutic window
of the compound in an assay system. Compounds were only considered as selective inhibitors in the
replicon assay when virus RNA replication was significantly inhibited (>70%) at concentrations not
adversely affecting the host cell metabolism. The observed antiviral effect of other compounds was
most likely related mainly to the pleiotropic or aspecific effect on the host cell.
Of the 20 newly synthesized conjugates, five (i.e., 3b–f) exhibited appealing antiviral activity with
EC50 values of 5.1–9.7 µM in the HCV 1b Huh 5-2 replicon system (Table 1). Three conjugates 3b, 3d,
and 3e displayed a significant window of selectivity with SI of 12–21.
Table 1. Anti-metabolic and antiviral effect of conjugated compounds on HCV 1b subgenomic replicon
replication in Huh 5-2 cells.
Compound a CC50 b (µM) EC50 c (µM) SI d
3a 122 30 4.1
3b 83 7.2 12
3c 85 9.7 8.8
3d 75 5.1 15
3e 173 8.4 21
3f 49 6.7 7.3
3g 75 15 5.1
7a 128 59 2.2
7b 122 26 4.7
7c 85 14 6.3
7d 107 19 5.7
7e 119 34 3.5
9a 109 61 1.8
9b 105 73 1.4
9d 93 70 1.3
9e 102 102 1.0
9f 106 106 1.0
11b 102 102 1.0
11e 99 99 1.0
11f 103 103 1.0
12a e [11] 90 27 3.4
12d e [11] 42 4.0 10
12e e [11] 27 10 2.8
coumarin >500 >150 -
imidazole >500 >150 -
a Interferon α-2b was used as a (positive) reference compound at 10,000 units/well and reduced the signal in
the viral RNA (luciferase) assay to background levels. The values were obtained as the average of triplicate
determinations; b The concentration of a compound with an adverse effect of 50% was observed on the host cell
metabolism, as determined by the MTS method; c The concentration of a compound at which virus replication
was inhibited by 50% was observed, as determined by real-time quantitative RT-PCR; d Selectivity index (ratio
of CC50 to EC50); e Reference known compounds published in [11].
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3. Structure–Activity Relationship: Essential Moieties and Functional Groups
This work established four new sets of conjugated compounds in the family of imidazole–,
(1-ribofuranosyl)imidazole–, inosine–, and guanosine–coumarins as shown in Schemes 1–3. All of the
conjugates had a –SCH2– joint to connect a coumarin moiety to an imidazole moiety. The substituents
in these conjugated compounds included F, Cl, Br, Me, and OMe. Close examination of their EC50,
CC50, and SI values shown in Table 1 allows us to deduce their SAR.
Attachment of the coumarin moiety to the imidazole nucleus generated conjugates with important
anti-HCV activity. Successful examples include 3b–e with EC50 = 5.1–9.7 µM and SI = 8.8–21. Besides,
attachment of a substituent (e.g., F, Cl, Br, and OMe) to the coumarin nucleus increased the potency
and the SI value by a factor of 2.1–5.1 (cf. 3b–e vs. 3a).
An Me group could be introduced onto the imidazole nucleus, while the resultant conjugates
without an N–H proton maintained a similar order of anti-HCV activity and selectivity (cf. 3f and 3g
with EC50 = 6.7 and 15 µM, respectively; SI = 7.3 and 5.1, respectively). On the other hand, introduction
of a β-D-ribofuranosyl moiety to the thiomethylene-linked imidazole–coumarin conjugates led to a
triply hybrid compound (i.e., 7a–e), some of which also exhibited anti-HCV activity (EC50 = 14 and
19 µM for 7c and 7d, respectively). In contrast to the ribosylated form at the N(1) position of the
imidazole nucleus, the N–H group at that position allowed for an incremental SI value (cf. 3a–e vs.
7a–e). Accordingly, the imidazole nucleus bearing an H was considered as an ideal core for conjugation
with coumarins.
The conjugated compounds with the imidazole nucleus had a higher selectivity than those
(i.e., 12a,d,e) [11] with a benzimidazole nucleus as shown below (Figure 2). It is due to lower cytotoxicity
associated with the conjugates 3a,d,e (cf. 3a vs. 12a, 3d vs. 12d and 3e vs. 12e). Moreover, the
conjugated compounds bearing a simple imidazole nucleus showed greater anti-HCV activity than
the corresponding conjugated compounds bearing an inosine or a guanosine nucleus by one order
(cf. 3 vs. 9, and 3 vs. 11).
Figure 2. Structure of benzimidazole–coumarin conjugates.
4. Experimental Section
4.1. General Procedures
All reactions were carried out in oven-dried glassware (120 ˝C) under an atmosphere of
nitrogen unless indicated otherwise. Dichloromethane, acetone, and methanol were purchased from
Mallinckrodt Chemical Co. (Dublin, Ireland). Acetonitrile was purchased from Fischer Scientific Co.
(Hampton, NH, USA). Ethyl acetate (EtOAc) and hexanes from Mallinckrodt Chemical Co. were
dried and distilled from CaH2. Trimethylsilyl trifluoro-methanesulfonate (Me3SiOTf) was purchased
from Fluka Chemika (St. Louis, MO, USA). N,O-Bistrimethylsilylacetamide (BTSA) was purchased
from Merck & Co. (Kenilworth, NJ, USA). Aqueous ammonium hydroxide was purchased from
J. T. Baker Chemical Co. (Center Valley, PA, USA). p-Toluenesulfonic acid monohydrate (PTSA),
1H-imidazole-2-thiol (1a), and 1-methyl-imidazole-2-thiol (1b) were purchased from Sigma-Aldrich
Chemical Co. (St. Louis, MO, USA). 1,2,3,5-Tetra-O-acetyl-β-D-ribofuranose was purchased from Alfa
Aesar Chemical Co. (Ward Hill, MA, USA). 3-(Chloromethyl)coumarins [47] 2a–e, 8-mercaptoinosine
8 [40], and 8-mercaptoguanosine 10 [41], were prepared according to the reported methods.
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Melting points were obtained with a MP-2D melting point apparatus (Fargo, New Taipei City,
Taiwan). Analytical thin layer chromatography (TLC) was performed on pre-coated plates (silica
gel 60 F-254) purchased from Merck & Co. (Kenilworth, NJ, USA). Purification by gravity column
chromatography was carried out by use of Silicycle (Quebec, QC, Canada) ultra pure silica gel (particle
size 40–63 µm, 230–400 mesh). High performance liquid chromatography (HPLC) was performed
on two Waters 515 HPLC pumps equipped with a Waters 2489 UV/visible detector (Milford, MA,
USA) and a Thermo (Waltham, MA, USA) 5 µm Hypersil ODS (250 mm ˆ 4.6 mm i.d.). Purity of all
compounds was >98.0%, as checked by HPLC.
Infrared (IR) spectra were measured on a model Spectrum One B spectrophotometer (Perkin-Elmer,
Waltham, MA, USA). Absorption intensities are recorded with the following abbreviations: s, strong;
m, medium; w, weak. High-resolution mass spectra were obtained by means of a JMS-700 mass
spectrometer (JEOL, Tokyo, Japan). Proton NMR spectra were obtained on a Mercury-400 (400 MHz)
spectrometer (Varian, Palo Alto, CA, USA) or an AC-400 (400 MHz) spectrometer (Bruker, Billerica,
MA, USA) using chloroform-d, or dimethylsulfoxide-d6 as solvents. Proton NMR chemical shifts
are referenced to the CHCl3 singlet (δ 7.24 ppm), and the center of DMSO-d6 quintet (δ 2.49 ppm).
Carbon-13 NMR spectra were recorded on a Varian Mercury-400 (100 MHz) spectrometer or Bruker
AC-400 (100 MHz) spectrometer using chloroform-d, dimethylsulfoxide-d6, or pyridine-d5 as solvents.
Carbon-13 chemical shifts are referenced to the center of the CDCl3 triplet (δ 77.0 ppm), the DMSO-d6
septet (δ 39.5 ppm), and the pyridine-d5 triplet (δ 150.4 ppm). Multiplicities are recorded with
the following abbreviations: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; J, coupling
constant (hertz).
4.2. Standard Procedure for the Synthesis of Imidazole–Coumarin Conjugates 3, 7, 9, and 11
To a solution containing a thione (1, 6, 8, or 10, 1.0 equiv) in water (2.5 mL) and acetonitrile
(1.5 mL) was added saturated aqueous ammonium hydroxide. After the solution was stirred at
room temperature for 30 min, a 3-(chloromethyl)coumarin (2, 1.5 equiv) was added and stirring was
continued at room temperature for 15 min to 2.0 h. Acetonitrile therein was removed under reduced
pressure and water was further removed under reduced pressure over P2O5 with a Kügelrohr GKR-51
apparatus (BUCHI, Flawil, Switzerland). The residue was purified by use of column chromatography
packed with silica gel to give the desired products with purity of >98.0%, as determined by HPLC
(see Supplementary Materials).
4.2.1. 2-[(Coumarin-3’-yl)methylthio]imidazole (3a)
The standard procedure was followed by use of 1H-imidazole-2-thiol (1a, 28.6 mg, 0.286 mmol,
1.0 equiv), aqueous ammonium hydroxide (0.25 mL), and 3-(chloromethyl)coumarin (2a, 66.7 mg,
0.343 mmol, 1.2 equiv). After the solution was stirred at room temperature for 2.0 h and then worked
up, the residue was purified by use of column chromatography (5.0% methanol in dichloromethane
as the eluent) to give 3a (63.4 mg, 0.246 mmol) in 86% yield as a white solid: mp (recrystallized from
EtOH) 252.0–252.8 ˝C; 1H-NMR (CDCl3, 400 MHz) δ 7.58 (s, 1H, O=C–C=CH), 7.39 (s, 2H, 2 ˆ NCH),
7.35–7.29 (m, 2H, 2 ˆ ArH), 7.14–7.10 (m, 2H, 2 ˆ ArH), 4.33 (s, 2H, SCH2); 13C-NMR (pyridine-d5,
100 MHz) δ 160.77 (C=O), 153.77, 140.38, 143.12, 139.37, 131.37, 128.18, 126.19, 124.58, 119.72, 116.42,
34.86 (SCH2); IR (KBr) 3307 (br, NH), 1713 (s, C=O), 1616 (m), 1587 (m), 1122 (m) cm´1; MS (FAB+)
m/z 259 (MH+, 27), 154 (100), 137 (57), 107 (24), 89 (24). HRMS m/z calcd for C13H10N2O2S: 258.0463,
found: 258.0462.
4.2.2. 2-[(6’-Fluorocoumarin-3’-yl)methylthio]imidazole (3b)
The standard procedure was followed by use of 1H-imidazole-2-thiol (1a, 29.1 mg, 0.291 mmol,
1.0 equiv), aqueous ammonium hydroxide (0.25 mL), and 3-(chloromethyl)-6-fluorocoumarin (2b, 74.2 mg,
0.349 mmol, 1.2 equiv). After the solution was stirred at room temperature for 2.0 h and then worked
up, the residue was purified by use of column chromatography (5.0% methanol in dichloromethane as
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the eluent) to give 3b (59.9 mg, 0.218 mmol) in 75% yield as a white solid: mp (recrystallized from
EtOH) 258.6–259.4 ˝C; 1H-NMR (DMSO-d6, 400 MHz) δ 7.58 (s, 1H, O=C–C=CH), 7.51–7.43 (m, 3H,
3 ˆ ArH), 7.13 (s, 1H, 1 ˆ NCH), 6.95 (s, 1H, 1 ˆ NCH), 3.99 (s, 2H, SCH2); 13C-NMR (pyridine-d5,
100 MHz) δ 160.45 (C=O), 160.01, 157.61, 139.36, 127.33, 125.10, 120.56, 118.62, 118.37, 118.14, 113.54,
113.30, 34.71 (SCH2); IR (KBr) 3306 (br, NH), 1713 (s, C=O), 1619 (m), 1504 (m), 1188 (m) cm´1;
MS (FAB+) m/z 277 (MH+, 19), 157 (31), 137 (22), 107 (9), 79 (100), 78 (23). HRMS m/z calcd for
C13H9N2O2FS: 276.0369, found: 276.0368.
4.2.3. 2-[(6’-Chlorocoumarin-3’-yl)methylthio]imidazole (3c)
The standard procedure was followed by use of 1H-imidazole-2-thiol (1a, 25.6 mg, 0.256 mmol,
1.0 equiv), aqueous ammonium hydroxide (0.25 mL), and 3-(chloromethyl)-6-chlorocoumarin (2c,
70.3 mg, 0.307 mmol, 1.2 equiv). After the solution was stirred at room temperature for 2.0 h and
then worked up, the residue was purified by use of column chromatography (5.0% methanol in
dichloromethane as the eluent) to give 3c (48.6 mg, 0.166 mmol) in 65% yield as a white solid: mp
(recrystallized from EtOH) 266.2–270.0 ˝C; 1H-NMR (DMSO-d6, 400 MHz) δ 7.73 (s, 1H, ArH), 7.60 (d,
1H, J = 8.8 Hz, ArH), 7.57 (s, 1H, O=C—C=CH), 7.43 (d, 1H, J = 8.8 Hz, ArH), 7.13 (s, 1H, NCH), 6.96 (s,
1H, NCH), 3.98 (s, 2H, SCH2); 13C-NMR (pridine-d5, 100 MHz) δ 160.26 (C=O), 152.08, 139.16, 139.08,
131.06, 129.28, 127.42, 125.11, 122.97, 120.85, 118.05, 34.64 (SCH2); IR (KBr) 3309 (br, NH), 1714 (s, C=O),
1615 (m), 1504 (m), 1189 (m) cm´1; MS (FAB+) m/z 293 (MH+, 14), 154 (100), 137 (57), 107 (22), 89 (23),
77 (20). HRMS m/z calcd for C13H9N2O2ClS: 292.0073, found: 292.0074.
4.2.4. 2-[(6’-Bromocoumarin-3’-yl)methylthio]imidazole (3d)
The standard procedure was followed by use of 1H-imidazole-2-thiol (1a, 28.8 mg, 0.288 mmol,
1.0 equiv), aqueous ammonium hydroxide (0.25 mL), and 3-(chloromethyl)-6-bromocoumarin (2d, 94.5 mg,
0.345 mmol, 1.2 equiv). After the solution was stirred at room temperature for 2.0 h and then worked
up, the residue was purified by use of column chromatography (5.0% methanol in dichloromethane as
the eluent) to give 3d (71.8 mg, 0.213 mmol) in 74% yield as a white solid: mp (recrystallized from
EtOH) 276.8–277.4 ˝C; 1H-NMR (CDCl3, 400 MHz) δ7.84 (d, J = 2.4 Hz, 1H, ArH), 7.71 (dd, J = 8.8,
2.4 Hz, 1H, ArH), 7.56 (s, 1H, O=C–C=CH), 7.37 (d, J = 8.8 Hz, 1H, ArH), 7.04 (s, 2H, 2 ˆ NCH), 3.98 (s,
2H, SCH2); 13C-NMR (pyridine-d5/DMSO-d6, 100 MHz) δ 160.23 (C=O), 152.09, 139.40, 137.95, 134.26,
130.28, 126.27, 126.07, 120.93, 118.52, 116.71, 34.38 (SCH2); IR (KBr) 3307 (br, NH), 1714 (s, C=O), 1620
(m), 1504 (m), 1189 (m), 1123 (m) cm´1; MS (FAB+) m/z 337 (MH+, 18), 154 (100), 137 (55), 107 (24), 89
(29), 77 (21). HRMS m/z calcd for C13H9N2O2BrS: 335.9568, found: 335.9649.
4.2.5. 2-[(8’-Methoxycoumarin-3’-yl)methylthio]imidazole (3e)
The standard procedure was followed by use of 1H-imidazole-2-thiol (1a, 28.7 mg, 0.287 mmol,
1.0 equiv), aqueous ammonium hydroxide (0.25 mL), and 3-(chloromethyl)-8-methoxycoumarin (2e,
76.6 mg, 0.344 mmol, 1.2 equiv). After the solution was stirred at room temperature for 2.0 h and
then worked up, the residue was purified by use of column chromatography (5.0% methanol in
dichloromethane as the eluent) to give 3e (66.3 mg, 0.229 mmol) in 80% yield as a white solid: mp
(recrystallized from EtOH) 269.8–270.6 ˝C; 1H-NMR (DMSO-d6, 400 MHz) δ 7.55 (s, 1H, O=C–C=CH),
7.31–7.21 (m, 2H, ArH), 7.10–7.09 (m, 1H, ArH), 7.08 (s, 1H, NCH), 6.97 (s, 1H, NCH), 3.98 (s, 2H,
SCH2), 3.89 (s 3H, OCH3); 13C-NMR (pyridine-d5/DMSO-d6, 100 MHz) δ 160.45 (C=O), 146.80, 142.83,
140.69, 138.74, 125.60, 124.54, 122.96, 119.91, 119.71, 119.36, 113.62, 55.93 (OCH3), 34.52 (SCH2); IR (KBr)
3307 (br, NH), 1713 (s, C=O), 1615 (m), 1504 (m), 1189 (m) cm´1; MS (FAB+) m/z 289 (MH+, 15), 154
(100), 137 (52), 107 (28), 89 (23), 77 (24). HRMS m/z calcd for C14H12N2O3S: 288.0569, found: 288.0570.
4.2.6. 1-Methyl-2-[(coumarin-3’-yl)methylthio]imidazole (3f)
The standard procedure was followed by use of 1-methyl-imidazole-2-thiol (1b, 33.2 mg,
0.291 mmol, 1.0 equiv), aqueous ammonium hydroxide (0.25 mL), and 3-(chloromethyl)coumarin (2a,
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85.1 mg, 0.437 mmol, 1.5 equiv). After the solution was stirred at room temperature for 2.0 h and then
worked up, the residue was purified by use of column chromatography (40% dichloromethane in
EtOAc as the eluent) to give 3f (54.9 mg, 0.201 mmol) in 69% yield as a white solid: mp (recrystallized
from EtOH) 244.2–244.8 ˝C; 1H-NMR (CDCl3, 400 MHz) δ 7.53 (s, 1H, O=C–C=CH), 7.45 (t, J = 7.2 Hz,
1H, ArH), 7.34 (s, J = 7.8 Hz, 1H, ArH), 7.28–7.19 (m, 2H, 2 ˆ ArH), 7.05 (s, 1H, NCH), 6.85 (s, 1H,
NCH), 4.12 (s, 2H, SCH2), 3.47 (s, 3H, NCH3); 13C-NMR (CDCl3, 100 MHz) δ 160.82 (C=O), 153.45,
140.55, 131.3129.47, 127.77, 125.01, 124.45, 122.57, 119.15, 116.67, 116.47, 33.92 (SCH2), 33.20 (CH3); IR
(KBr) 1713 (s, C=O), 1616 (m), 1519 (m), 1170 (m) cm´1; MS (FAB+) m/z 272 (M+, 30), 154 (100), 136
(77), 89 (33), 77 (20), 55 (60); HRMS m/z calcd for C14H12N2O2S: 272.0619, found: 272.0620.
4.2.7. 1-Methyl-2-[(6’-chlorocoumarin-3’-yl)methylthio]imidazole (3g)
The standard procedure was followed by use of 1-methyl-imidazole-2-thiol (1b, 36.2 mg,
0.317 mmol, 1.0 equiv), aqueous ammonium hydroxide (0.25 mL), and 3-(chloromethyl)-6-
chlorocoumarin (2c, 109 mg, 0.476 mmol, 1.5 equiv). After the solution was stirred at room temperature
for 2.0 h and then worked up, the residue was purified by use of column chromatography (40%
dichloromethane in EtOAc as the eluent) to give 3g (70.5 mg, 0.231 mmol) in 73% yield as a white solid:
mp (recrystallized from EtOH) 256.2–257.2 ˝C; 1H-NMR (CDCl3, 400 MHz) δ 7.51 (s, 1H, O=C–C=CH),
7.40 (d, J = 8.8 Hz, 1H, ArH), 7.34 (s, 1H, ArH), 7.22 (d, J = 8.8 Hz, 1H, ArH), 7.06 (s, 1H, NCH), 6.87 (s,
1H, NCH), 4.12 (s, 2H, SCH2), 3.49 (s, 3H, NCH3); 13C-NMR (CDCl3, 100 MHz) δ 160.27 (C=O), 151.80,
140.40, 139.27, 131.23, 129.73, 129.49, 126.98, 126.38, 122.66, 120.22, 117.92, 33.56 (SCH2), 33.20 (CH3); IR
(KBr) 1705 (s, C=O), 1615 (m), 1518 (m), 1233 (m) cm´1; MS (FAB+) m/z 307 (MH+, 100), 154 (66), 136
(59), 77 (30), 55 (35), 77 (20); HRMS m/z calcd for C14H11N2O2ClS: 306.0230, found: 306.0233.
4.2.8. 1-(2’,3’,5’-Tri-O-acetyl-β-D-ribofuranos-1’-yl)imidazole-2-thiol (5)
To a solution of 1H-imidazole-2-thiol (1a, 375 mg, 3.74 mmol, 1.0 equiv) in dry acetonitrile
(30 mL) was added BTSA (1.20 mL, 4.91 mmol, 1.3 equiv) under nitrogen atmosphere according
to the Vorbrüggen procedure [43]. After the solution was stirred at 60 ˝C for 30 min,
1,2,3,5-tetra-O-acetyl-β-D-ribofuranose (4, 1.25 g, 3.93 mmol, 1.1 equiv) and Me3SiOTf (0.711 mL,
3.93 mmol, 1.1 equiv) were added in sequence. The reaction mixture was heated to 80 ˝C and stirred
for 18 h. Excess solvent was removed under reduced pressure, and the residue was treated with 20%
aqueous NaHCO3 solution (30 mL). The aqueous layer was extracted with ethyl acetate (3 ˆ 25 mL).
The combined organic layers were washed with brine (30 mL), dried over MgSO4 (s), filtered, and
concentrated under reduced pressure to afford a residue, which was purified by use of column
chromatography (20% hexanes in EtOAc as the eluent) to give 5 (698.4 mg, 1.945 mmol) in 52% yield.
1H-NMR (CDCl3, 400 MHz) δ 6.90 (s, 1H, NCH), 6.72 (s, 1H, NCH), 6.47 (s, 1H, H-1”), 5.44 (t, J = 5.2 Hz,
1H, H-2”), 5.31 (t, J = 5.2 Hz, 1H, H-3”), 4.38–4.36 (m, 1H, H-4”), 4.33–4.28 (m, 2H, 2 ˆ H-5”), 2.13
(s, 3H, CO2CH3), 2.11 (s, 3H, CO2CH3), 2.09 (s, 3H, CO2CH3). These data are consistent with those
reported [48].
4.2.9. 1-β-D-Ribofuranosyl-imidazole-2-thiol (6)
To a solution containing 5 (82.6 mg, 0.230 mmol, 1.0 equiv) in methanol (10 mL) was added
potassium carbonate (31.9 mg, 0.231 mmol, 1.0 equiv) at room temperature. After the solution was
stirred at 0 ˝C for 12 h, it was concentrated under reduced pressure. To the residue was added saturated
aqueous NH4Cl (20 mL), which was extracted with CHCl3 (3 ˆ 20 mL). The combined organic layers
were washed with brine (20 mL), dried over MgSO4 (s), filtered, and concentrated under reduced
pressure. The residue was then purified by use of column chromatography (10% MeOH in EtOAc as
the eluent) to give 6 (49.1 mg, 0.212 mmol) in 92% yield. 1H-NMR (DMSO-d6, 400 MHz) δ 7.29 (s, 1H,
NCH), 6.91 (s, 1H, NCH), 6.02 (s, 1H, H-1”), 5.27 (d, J = 6.6 Hz, 1H, OH), 5.03 (d, J = 4.0 Hz, 1H, OH),
4.98 (t, J = 5.2 Hz, 1H, OH), 4.07–4.04 (m, 1H, H-2”), 4.03–3.99 (m, 1H, H-3”), 3.83–3.81 (m, 1H, H-4”),
3.63–3.53 (m, 2H, 2 ˆ H-5”). These data are consistent with those reported [48].
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4.2.10. 1-(β-D-Ribofuranos-1”-yl)-2-[(coumarin-3’-yl)methylthio]imidazole (7a)
The standard procedure was followed by use of 1-β-D-ribofuranosyl-imidazole-2-thiol (6, 43.1 mg,
0.186 mmol, 1.0 equiv), aqueous ammonium hydroxide (0.25 mL), and 3-(chloromethyl)coumarin
(2a, 43.4 mg, 0.223 mmol, 1.2 equiv). After the solution was stirred at room temperature for 2.0 h
and then worked up, the residue was purified by use of column chromatography (10% MeOH in
dichloromethane as the eluent) to give 7a (53.7 mg, 0.165 mmol) in 74% yield as a white solid: mp
(recrystallized from EtOH) 164.6–165.4 ˝C; 1H-NMR (DMSO-d6, 400 MHz) δ 7.66 (s, 1H, O=C–C=CH),
7.58–7.54 (m, 2H, 2 ˆ ArH), 7.49 (s, 1H, NCH), 7.38 (d, J = 8.4 Hz, 1H, ArH), 7.30 (t, J = 7.6 Hz, 1H,
ArH), 6.99 (s, 1H, NCH), 5.67 (d, J = 7.2 Hz, 1H, H-1”), 5.37 (d, J = 6.4 Hz, 1H, OH), 5.17 (d, J = 4.4 Hz,
1H, OH), 4.93 (t, J = 5.2 Hz, 1H, OH), 4.16–4.11 (m, 1H, H-2”), 4.04 (s, 2H, SCH2), 3.99–3.98 (m, 1H,
H-3”), 3.78–3.76 (m, 1H, H-4”), 3.43–3.39 (m, 2H, 2 ˆ H-5”); 13C-NMR (DMSO-d6, 100 MHz) δ 160.03
(C=O), 151.94, 140.67, 139.65, 131.57, 129.62, 128.20, 124.59, 124.44, 119.54, 118.97, 116.00, 88.13, 85.58,
75.10, 70.55, 61.36, 34.27 (SCH2); IR (KBr) 3387 (br, OH), 1698 (s, C=O), 1609 (m), 1457 (m), 1111 (m)
cm´1; MS (FAB+) m/z 391 (MH+, 66), 154 (100), 137 (54), 77 (33); HRMS m/z calcd for C18H18N2O6S:
390.0886, found: 390.0891.
4.2.11. 1-(β-D-Ribofuranos-1”-yl)-2-[(6’-fluorocoumarin-3’-yl)methylthio]imidazole (7b)
The standard procedure was followed by use of 1-β-D-ribofuranosyl-imidazole-2-thiol (6,
44.9 mg, 0.193 mmol, 1.0 equiv), aqueous ammonium hydroxide (0.25 mL), and 3-(chloromethyl)-6-
fluorocoumarin (2b, 49.3 mg, 0.232 mmol, 1.2 equiv). After the solution was stirred at room temperature
for 2.0 h and then worked up, the residue was purified by use of column chromatography (10% MeOH
in dichloromethane as the eluent) to give 7b (62.9 mg, 0.154 mmol) in 80% yield as a white solid: mp
(recrystallized from EtOH) 171.2–172.4 ˝C; 1H-NMR (DMSO-d6, 400 MHz) δ 7.62 (s, 1H, O=C–C=CH),
7.50 (s, 1H, ArH), 7.47–7.42 (m, 3H, 2 ˆ ArH + NCH), 7.00 (s, 1H, NCH), 5.65 (d, J = 6.4 Hz, 1H, H-1”),
5.36 (d, J = 6.8 Hz, 1H, OH), 5.18 (d, J = 7.6 Hz, 1H, OH), 4.94 (t, J = 5.2 Hz, 1H, OH), 4.16–4.11 (m,
1H, H-2”), 4.03 (s, 2H, SCH2), 4.00–3.97 (m, 1H, H-3”), 3.77–3.74 (m, 1H, H-4”), 3.42–3.38 (m, 2H, 2 ˆ
H-5”); 13C-NMR (CDCl3, 100 MHz) δ 159.73 (C=O), 149.28, 139.60, 139.51, 129.64, 125.67, 119.97, 119.52,
118.78, 118.54, 117.96, 113.49, 88.08, 85.54, 75.01, 70.49, 61.32, 34.22 (SCH2); IR (KBr) 3388 (br, OH), 1694
(s, C=O), 1580 (m), 1489 (m), 1265 (m), 1078 (m) cm´1; MS (FAB+) m/z 409 (MH+, 54), 154 (100), 137
(57), 77 (31), 55 (66); HRMS m/z calcd for C18H17N2O6FS: 408.0791, found: 408.0794.
4.2.12. 1-(β-D-Ribofuranos-1”-yl)-2-[(6’-chlorocoumarin-3’-yl)methylthio]imidazole (7c)
The standard procedure was followed by use of 1-β-D-ribofuranosyl-imidazole-2-thiol (6,
44.6 mg, 0.192 mmol, 1.0 equiv), aqueous ammonium hydroxide (0.25 mL), and 3-(chloromethyl)-
6-chlorocoumarin (2c, 52.8 mg, 0.231 mmol, 1.2 equiv). After the solution was stirred at room
temperature for 2.0 h and then worked up, the residue was purified by use of column chromatography
(10% MeOH in dichloromethane as the eluent) to give 7c (61.2 mg, 0.144 mmol) in 75% yield as a white
solid: mp (recrystallized from EtOH) 178.8–179.6 ˝C; 1H-NMR (DMSO-d6, 400 MHz) δ 7.69 (s, 1H,
O=C–C=CH), 7.60 (s, 1H, ArH), 7.59–7.57 (m, 2H, 2 ˆ ArH), 7.49 (s, 1H, NCH), 7.41 (d, J = 8.8 Hz, 1H,
ArH), 7.00 (s, 1H, NCH), 5.65 (d, J = 6.4 Hz, 1H, H-1”), 5.34 (d, J = 6.4 Hz, 1H, OH), 5.16 (d, J = 4.8 Hz,
1H, OH), 4.92 (t, J = 5.2 Hz, 1H, OH), 4.15–4.11 (m, 1H, H-2”), 4.02 (s, 2H, SCH2), 4.00–3.97 (m, 1H,
H-3”), 3.77–3.74 (m, 1H, H-4”), 3.41–3.38 (m, 2H, 2 ˆ H-5”); 13C-NMR (CDCl3, 100 MHz) δ 159.53
(C=O), 151.54, 139.44, 139.31, 131.05, 129.67, 128.27, 127.17, 125.75, 120.38, 119.54, 117.98, 88.07, 85.55,
75.01, 70.50, 61.31, 34.31 (SCH2); IR (KBr) 3399 (br, OH), 1695 (s, C=O), 1615 (m), 1580 (m), 1441 (m),
1265 (m), 1173 (m) cm´1; MS (FAB+) m/z 425 (MH+, 55), 154 (100), 137 (53), 77 (35), 55 (61); HRMS m/z
calcd for C18H17N2O6ClS: 424.0496, found: 424.0580.
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4.2.13. 1-(β-D-Ribofuranos-1”-yl)-2-[(6’-bromocoumarin-3’-yl)methylthio]imidazole (7d)
The standard procedure was followed by use of 1-β-D-ribofuranosyl-imidazole-2-thiol (6,
47.2 mg, 0.203 mmol, 1.0 equiv), aqueous ammonium hydroxide (0.25 mL), and 3-(chloromethyl)-
6-bromocoumarin (2d, 66.7 mg, 0.244 mmol, 1.2 equiv). After the solution was stirred at room
temperature for 2.0 h and then worked up, the residue was purified by use of column chromatography
(10% MeOH in dichloromethane as the eluent) to give 7d (79.8 mg, 0.171 mmol) in 84% yield as a
white solid: mp (recrystallized from EtOH) 188.8–189.4 ˝C; 1H-NMR (DMSO-d6, 400 MHz) δ 7.82 (s,
1H, O=C–C=CH), 7.72–7.69 (m, 1H, ArH), 7.60 (s, 1H, ArH), 7.50 (s, 1H, NCH), 7.36 (d, J = 8.8 Hz, 1H,
ArH), 7.01 (s, 1H, NCH), 5.65 (d, J = 7.2 Hz, 1H, H-1”), 5.36 (d, J = 6.8 Hz, 1H, OH), 5.17 (d, J = 4.4 Hz,
1H, OH), 4.93 (t, J = 5.2 Hz, 1H, OH), 4.16–4.11 (m, 1H, H-2”), 4.02 (s, 2H, SCH2), 4.00–3.97 (m, 1H,
H-3”), 3.76–3.74 (m, 1H, H-4”), 3.41–3.38 (m, 2H, 2 ˆ H-5”); 13C-NMR (CDCl3, 100 MHz) δ 159.46
(C=O), 151.95, 139.39, 139.23, 133.82, 130.13, 129.63, 125.68, 120.86, 119.56, 118.25, 116.09, 88.07, 85.56,
75.02, 70.50, 61.30, 34.33 (SCH2); IR (KBr) 3400 (br, OH), 1693 (s, C=O), 1599 (m), 1479 (m), 1399 (m),
1263 (m), 1172 (m) cm´1; MS (FAB+) m/z 469 (MH+, 45), 154 (100), 137 (55), 77 (32), 55 (60); HRMS m/z
calcd for C18H17N2O6BrS: 467.9991, found: 468.0072.
4.2.14. 1-(β-D-Ribofuranos-1”-yl)-2-[(8’-methoxycoumarin-3’-yl)methylthio]imidazole (7e)
The standard procedure was followed by use of 1-β-D-ribofuranosyl-imidazole-2-thiol (6,
46.8 mg, 0.201 mmol, 1.0 equiv), aqueous ammonium hydroxide (0.25 mL), and 3-(chloromethyl)-
8-methoxycoumarin (2e, 53.8 mg, 0.241 mmol, 1.2 equiv). After the solution was stirred at room
temperature for 2.0 h and then worked up, the residue was purified by use of column chromatography
(10% MeOH in dichloromethane as the eluent) to give 7e (61.2 mg, 0.145 mmol) in 72% yield as a
white solid: mp (recrystallized from EtOH) 169.6–170.4 ˝C; 1H-NMR (DMSO-d6, 400 MHz) δ 7.63 (s,
1H, O=C–C=CH), 7.49 (s, 1H, NCH), 7.25–7.20 (m, 2H, 2 ˆ ArH), 7.10–7.08 (m, 1H, ArH), 6.99 (s, 1H,
NCH), 5.66 (d, J = 6.0 Hz, 1H, H-1”), 5.38 (d, J = 6.8 Hz, 1H, OH), 5.18 (d, J = 4.4 Hz, 1H, OH), 4.94
(t, J = 5.2 Hz, 1H, OH), 4.16–4.11 (m, 1H, H-2”), 4.07 (s, 2H, SCH2), 4.03–3.97 (m, 1H, H-3”), 3.88 (s,
3H, OCH3), 3.79–3.76 (m, 1H, H-4”), 3.43–3.40 (m, 2H, 2 ˆ H-5”); 13C-NMR (DMSO-d6, 100 MHz) δ
159.71 (C=O), 146.33, 142.24, 140.85, 139.58, 129.57, 124.60, 124.50, 119.49, 119.36, 113.86, 88.10, 85.54,
75.05, 70.49, 61.33, 56.08 (OCH3), 34.14 (SCH2); IR (KBr) 3403 (br, OH), 1695 (s, C=O), 1579 (m), 1402
(m), 1265 (m), 1102 (m), 1078 (m) cm´1; MS (FAB+) m/z 421 (MH+, 15), 154 (100), 137 (30), 77 (66), 55
(67); HRMS m/z calcd for C19H20N2O7S: 420.0991, found: 420.0987.
4.2.15. 8-[(Coumarin-3’-yl)methylthio]inosine (9a)
The standard procedure was followed by use of 8 (48.7 mg, 0.162 mmol, 1.0 equiv), water
(2.5 mL), acetonitrile (1.5 mL), aqueous ammonium hydroxide (0.15 mL), and 3-(chloromethyl)
coumarin (2a, 37.8 mg, 0.194 mmol, 1.2 equiv). It was stirred at room temperature for 30 min and then
worked up. The residue was purified by use of column chromatography (10% methanol in CH2Cl2
as the eluent) to give 9a (52.4 mg, 0.114 mmol) in 70% yield as a white solid: mp (recrystallized from
dichloromethane/methanol) 160.9–162.5 ˝C; 1H-NMR (DMSO-d6, 400 MHz) δ 8.06 (s, 1H, H-2), 8.02 (s,
1H, CH=C–COO), 7.65–7.57 (m, 2H, 2 ˆ ArH), 7.41 (d, J = 8.4 Hz, 1H, ArH), 7.33 (dd, J = 7.6, 7.2 Hz, 1H,
ArH), 5.76 (d, J = 6.4 Hz, 1H, H-1”), 5.41 (d, J = 5.6 Hz, 1H, OH), 5.19 (d, J = 3.6 Hz, 1H, OH), 5.01–4.99
(br, 1H, OH), 4.89–4.85 (m, 1H, H-2”), 4.39 (d, J = 14.2 Hz, 1H, SCH), 4.35 (d, J = 14.2 Hz, 1H, SCH),
4.12–4.09 (m, 1H, H-3”), 3.88–3.85 (m, 1H, H-4”), 3.63–3.57 (m, 1H, H-5”), 3.50–3.44 (m, 1H, H-5”);
13C-NMR (DMSO-d6, 100 MHz) δ 160.07 (C=O), 155.37 (C=O), 152.89, 149.57, 146.63, 145.28, 141.20,
131.76, 128.37, 124.90, 124.60, 123.84, 118.74, 116.10, 88.74, 86.06, 71.16, 70.50, 61.81, 32.04 (SCH2); IR
(ATR) 3359 (br, OH + NH), 1707 (s, C=O), 1678 (s, C=O), 1583 (m), 1189 (m), 1051 (s) cm´1; MS (FAB+)
m/z 459 (MH+, 2), 327 (4), 221 (13), 147 (13), 55 (100); HRMS (FAB) calcd for (C20H18N4O7S + H)+:
459.0974, found: 459.0984.
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4.2.16. 8-[(6’-Fluorocoumarin-3’-yl)methylthio]inosine (9b)
The standard procedure was followed by use of 8 (56.7 mg, 0.189 mmol, 1.0 equiv), water (2.5 mL),
acetonitrile (1.5 mL), aqueous ammonium hydroxide (0.15 mL), and 3-(chloromethyl)-6-fluorocoumarin
(2b, 48.2 mg, 0.227 mmol, 1.2 equiv). It was stirred at room temperature for 30 min and then worked
up. The residue was purified by use of column chromatography (10% methanol in CH2Cl2 as the
eluent) to give 9b (74.4 mg, 0.156 mmol) in 83% yield as a white solid: mp (recrystallized from
dichloromethane/methanol) 168.3–169.1 ˝C; 1H-NMR (DMSO-d6, 400 MHz) δ 12.50–12.42 (br, 1H,
NH), 8.03 (s, 1H, H-2), 8.01 (s, 1H, CH=C–COO), 7.56–7.54 (m, 1H, ArH), 7.48–7.46 (m, 2H, 2 ˆ ArH),
5.76 (d, J = 6.4 Hz, 1H, H-1”), 5.43 (d, J = 6.0 Hz, 1H, OH), 5.23 (d, J = 4.4 Hz, 1H, OH), 5.01–4.99 (br, 1H,
OH), 4.89–4.85 (m, 1H, H-2”), 4.39 (d, J = 14.2 Hz, 1H, SCH), 4.34 (d, J = 14.2 Hz, 1H, SCH), 4.12–4.08
(m, 1H, H-3”), 3.88–3.84 (m, 1H, H-4”), 3.62–3.57 (m, 1H, H-5”), 3.50–3.44 (m, 1H, H-5”); 13C-NMR
(DMSO-d6, 100 MHz) δ 159.86 (C=O), 158.08 (d, C=O), 155.40, 149.60, 149.28, 146.51, 145.35, 140.09,
125.18, 124.99, 119.75 (d), 118.95 (d), 118.05 (d), 113.56 (d), 88.79, 86.15, 71.29, 70.45, 61.83, 32.09 (SCH2);
IR (ATR) 3359 (br, OH + NH), 1706 (s, C=O), 1676 (s, C=O), 1583 (m), 1452 (m), 1188 (m), 1061 (s)
cm´1; MS (FAB+) m/z 477 (MH+, 25), 345 (65), 289 (45), 154 (100), 120 (49); HRMS (FAB) calcd for
(C20H17FN4O7S + H)+: 477.0880, found: 477.0877.
4.2.17. 8-[(6’-Bromocoumarin-3’-yl)methylthio]inosine (9d)
The standard procedure was followed by use of 8 (45.8 mg, 0.153 mmol, 1.0 equiv), water
(2.5 mL), acetonitrile (1.5 mL), aqueous ammonium hydroxide (0.15 mL), and 6-bromo-3-(chloromethyl)
coumarin (2d, 50.2 mg, 0.184 mmol, 1.2 equiv). It was stirred at room temperature for 20 min and then
worked up. The residue was purified by use of column chromatography (10% methanol in CH2Cl2
as the eluent) to give 9d (66.4 mg, 0.126 mmol) in 80% yield as a white solid: mp (recrystallized from
dichloromethane/methanol) 169.1–170.5 ˝C; 1H-NMR (DMSO-d6, 400 MHz) δ 11.95–11.92 (br, 1H,
NH), 8.04 (s, 1H, H-2), 8.00 (s, 1H, CH=C–COO), 7.90 (d, J = 2.4 Hz, 1H, ArH), 7.73 (dd, J = 8.8, 2.4
Hz, 1H, ArH), 7.38 (d, J = 8.8 Hz, 1H, ArH), 5.76 (d, J = 6.8 Hz, 1H, H-1”), 5.42–5.40 (br, 1H, OH),
5.22–5.20 (br, 1H, OH), 4.96–4.94 (br, 1H, OH), 4.89–4.86 (m, 1H, H-2”), 4.38 (d, J = 14.4 Hz, 1H, SCH),
4.34 (d, J = 14.4 Hz, 1H, SCH), 4.12–4.09 (m, 1H, H-3”), 3.88–3.85 (m, 1H, H-4”), 3.62–3.59 (m, 1H, H-5”),
3.50–3.45 (m, 1H, H-5”); 13C-NMR (DMSO-d6, 100 MHz) δ 159.61 (C=O), 155.36 (C=O), 151.93, 149.58,
146.45, 145.32, 139.72, 134.08, 130.32, 125.19, 124.98, 120.66, 118.36, 116.21, 88.79, 86.15, 71.29, 70.45,
61.83, 32.09 (SCH2); IR (ATR) 3356 (br, OH + NH), 1708 (s, C=O), 1678 (s, C=O), 1585 (m), 1188 (m),
1022 (s) cm´1; MS (FAB+) m/z 537 (MH+, 2), 427 (13), 307 (19), 185 (26), 154 (100); HRMS (FAB) calcd
for (C20H17BrN4O7S + H)+: 537.0080, found: 537.0077.
4.2.18. 8-[(8’-Methoxycoumarin-3’-yl)methylthio]inosine (9e)
The standard procedure was followed by use of 8 (35.8 mg, 0.119 mmol, 1.0 equiv), water
(2.5 mL), acetonitrile (1.5 mL), aqueous ammonium hydroxide (0.15 mL), and 3-chloromethyl-
8-methoxycoumarin (2e, 41.9 mg, 0.201 mmol, 1.2 equiv). It was stirred at room temperature for
30 min and then worked up. The residue was purified by use of column chromatography (10%
methanol in CH2Cl2 as the eluent) to give 9e (46.7 mg, 95.6 µmol) in 80% yield as a white solid: mp
(recrystallized from dichloromethane/methanol) 162.3–164.1 ˝C; 1H-NMR (DMSO-d6, 400 MHz) δ
12.52–12.39 (br, 1H, NH), 8.04 (s, 1H, H-2), 8.03 (s, 1H, CH=C–COO), 7.28–7.23 (m, 2H, 2 ˆ ArH),
7.18–7.16 (m, 1H, ArH), 5.75 (d, J = 6.4 Hz, 1H, H-1”), 5.45–5.41 (br, 1H, OH), 5.23–5.21 (br, 1H, OH),
4.96 (dd, J = 6.0, 5.6 Hz, 1H, OH), 4.88–4.85 (m, 1H, H-2”), 4.39 (d, J = 14.0 Hz, 1H, SCH), 4.34 (d,
J = 14.0 Hz, 1H, SCH), 4.13–4.09 (m, 1H, H-3”), 3.89 (s, 3H, OCH3), 3.87–3.85 (m, 1H, H-4”), 3.62–3.59
(m, 1H, H-5”), 3.49–3.46 (m, 1H, H-5”); 13C-NMR (DMSO-d6, 100 MHz) δ 159.83 (C=O), 155.39 (C=O),
149.60, 146.69, 146.39, 145.31, 142.24, 141.15, 124.96, 124.67, 124.03, 119.49, 119.32, 114.13, 88.76, 86.15,
71.28, 70.46, 61.83, 56.10 (OCH3), 32.01 (SCH2); IR (ATR) 3354 (br, OH + NH), 1708 (s, C=O), 1692 (s,
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C=O), 1583 (m), 1189 (m), 1060 (s) cm´1; MS (ESI) m/z 488 (M+); HRMS (ESI) calcd for (C21H20N4O8S)+:
488.1002, found: 488.1011.
4.2.19. 8-[(6’-Methylcoumarin-3’-yl)methylthio]inosine (9f)
The standard procedure was followed by use of 8 (50.2 mg, 0.167 mmol, 1.0 equiv), water (2.5 mL),
acetonitrile (1.5 mL), aqueous ammonium hydroxide (0.15 mL), and 3-chloromethyl-6-methylcoumarin
(2f, 41.9 mg, 0.201 mmol, 1.2 equiv). It was stirred at room temperature for 15 min and then worked
up. The residue was purified by use of column chromatography (10% methanol in CH2Cl2 as the
eluent) to give 9f (64.6 mg, 0.137 mmol) in 82% yield as a white solid: mp (recrystallized from
dichloromethane/methanol) 156.8–158.4 ˝C; 1H-NMR (DMSO-d6, 400 MHz) δ 12.48–12.38 (br, 1H,
NH), 8.03 (s, 1H, H-2), 8.01 (s, 1H, CH=C–COO), 7.41–7.38 (m, 2H, 2 ˆ ArH), 7.30 (d, J = 8.4 Hz, 1H,
ArH), 5.75 (d, J = 6.4 Hz, 1H, H-1”), 5.43 (d, J = 5.2 Hz, 1H, OH), 5.22 (d, J = 2.4 Hz, 1H, OH), 4.95 (dd,
J = 6.0, 5.6 Hz, 1H, OH), 4.88–4.86 (m, 1H, H-2”), 4.38 (d, J = 14.0 Hz, 1H, SCH), 4.34 (d, J = 14.0 Hz,
1H, SCH), 4.12–4.09 (m, 1H, H-3”), 3.89–3.85 (m, 1H, H-4”), 3.64–3.58 (m, 1H, H-5”), 3.51–3.48 (m, 1H,
H-5”), 2.32 (s, 3H, CH3); 13C-NMR (DMSO-d6, 100 MHz) δ 160.26 (C=O), 155.37 (C=O), 151.07, 149.62,
146.77, 145.27, 141.16, 134.00, 132.66, 127.95, 124.95, 123.78, 118.50, 115.86, 88.76, 86.15, 71.29, 70.45,
61.85, 32.00 (SCH2), 20.17 (CH3); IR (ATR) 3345 (br, OH + NH), 1707 (s, C=O), 1692 (s, C=O), 1583 (m),
1188 (m), 1023 (s) cm´1; MS (FAB+) m/z 473 (MH+, 1), 341 (10), 185 (16), 109 (30), 55 (100); HRMS (FAB)
calcd for (C21H20N4O7S)+: 472.1053, found: 472.1060.
4.2.20. 8-[(6’-Fluorocoumarin-3’-yl)methylthio]guanosine (11b)
The standard procedure was followed by use of 10 (65.2 mg, 0.207 mmol, 1.0 equiv), water (5.0 mL),
acetonitrile (3.0 mL), aqueous ammonium hydroxide (0.25 mL), and 3-chloromethyl-6-fluorocoumarin
(2b, 52.8 mg, 0.248 mmol, 1.2 equiv). It was stirred at room temperature for 15 min and then worked
up. The residue was purified by use of column chromatography (15% methanol in CH2Cl2 as the
eluent) to give 11b (90.2 mg, 0.183 mmol) in 89% yield as a white solid: mp (recrystallized from
dichloromethane/methanol) 184.9–186.2 ˝C; 1H-NMR (DMSO-d6, 400 MHz) δ 10.70–10.66 (br, 1H,
NH), 7.90 (s, 1H, CH=C–COO), 7.53–7.42 (m, 3H, 3 ˆ ArH), 6.41 (s, 2H, NH2), 5.70 (d, J = 6.8 Hz, 1H,
H-1”), 5.35 (d, J = 6.0 Hz, 1H, OH), 5.07 (d, J = 4.8 Hz, 1H, OH), 4.94 (dd, J = 6.8, 5.2 Hz, 1H, OH),
4.89–4.85 (m, 1H, H-2”), 4.24 (d, J = 14.0 Hz, 1H, SCH), 4.19 (d, J = 14.0 Hz, 1H, SCH), 4.10–4.06 (m, 1H,
H-3”), 3.80–3.76 (m, 1H, H-4”), 3.62–3.56 (m, 1H, H-5”), 3.49–3.43 (m, 1H, H-5”); 13C-NMR (DMSO-d6,
100 MHz) δ 159.83 (C=O), 158.07 (d, C=O), 155.60, 153.10, 152.47, 149.25, 141.48, 139.84, 125.44, 119.81
(d), 118.83 (d), 118.00 (d), 117.42, 113.47 (d), 88.27, 85.74, 70.53, 61.96, 32.77 (SCH2); IR (ATR) 3146 (br,
OH + NH), 1723 (m, C=O), 1681 (s, C=O), 1626 (s), 1071(s) cm´1; MS (FAB+) m/z 492 (MH+, 35), 360
(62), 307 (98), 219 (23), 156 (100), 107 (100); HRMS (FAB) calcd for (C20H18FN5O7S + H)+: 492.0989,
found: 492.0996.
4.2.21. 8-[(8’-Methoxycoumarin-3’-yl)methylthio]guanosine (11e)
The standard procedure was followed by use of 10 (63.7 mg, 0.202 mmol, 1.0 equiv), water
(5.0 mL), acetonitrile (3.0 mL), aqueous ammonium hydroxide (0.25 mL), and 3-chloromethyl-8-
methoxycoumarin (2e, 54.0 mg, 0.243 mmol, 1.2 equiv). It was stirred at room temperature for 1.0 h
and then worked up. The residue was purified by use of column chromatography (10% methanol in
CH2Cl2 as the eluent) to give 11e (84.3 mg, 0.167 mmol) in 83% yield as a white solid: mp (recrystallized
from dichloromethane/methanol) 192.8–194.3 ˝C; 1H-NMR (DMSO-d6, 400 MHz) δ 10.68–10.64 (br,
1H, NH), 7.93 (s, 1H, CH=C–COO), 7.28–7.23 (m, 2H, 2 ˆ ArH), 7.16–7.14 (m, 1H, ArH), 6.42 (s, 2H,
NH2), 5.69 (d, J = 6.8 Hz, 1H, H-1”), 5.38 (d, J = 6.4 Hz, 1H, OH), 5.09 (d, J = 5.2 Hz, 1H, OH), 4.95 (dd,
J = 6.0, 5.6 Hz, 1H, OH), 4.88–4.84 (m, 1H, H-2”), 4.24 (d, J = 13.8 Hz, 1H, SCH), 4.19 (d, J = 13.8 Hz, 1H,
SCH), 4.09–4.05 (m, 1H, H-3”), 3.89 (s, 3H, OCH3), 3.80–3.77 (m, 1H, H-4”), 3.61–3.56 (m, 1H, H-5”),
3.49–3.43 (m, 1H, H-5”); 13C-NMR (DMSO-d6, 100 MHz) δ 159.87 (C=O), 155.68 (C=O), 153.14, 152.55,
146.41, 142.25, 141.73, 141.24, 124.66, 124.34, 119.47, 119.41, 117.38, 114.05, 88.26, 85.78, 70.53, 62.01,
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56.16 (OCH3), 32.63 (SCH2); IR (ATR) 3142 (br, OH + NH), 1714 (m, C=O), 1682 (s, C=O), 1274 (m),
1092 (m) cm´1; MS (FAB+) m/z 503 (M+, 2), 372 (10), 232 (11), 154 (45), 79 (100); HRMS (FAB) calcd for
(C21H21N5O8S)+: 503.1107, found: 503.1111.
4.2.22. 8-[(6’-Methylcoumarin-3’-yl)methylthio]guanosine (11f)
The standard procedure was followed by use of 10 (52.3 mg, 0.166 mmol, 1.0 equiv), water (5.0 mL),
acetonitrile (3.0 mL), aqueous ammonium hydroxide (0.25 mL), and 3-chloromethyl-6-methylcoumarin
(2f, 41.5 mg, 0.199 mmol, 1.2 equiv). It was stirred at room temperature for 30 min and then worked
up. The residue was purified by use of column chromatography (15% methanol in CH2Cl2 as the
eluent) to give 11f (59.6 mg, 0.122 mmol) in 74% yield as a white solid: 1H-NMR (DMSO-d6, 400 MHz)
δ 10.74–10.70 (br, 1H, NH), 7.90 (s, 1H, CH=C–COO), 7.40–7.38 (m, 2H, 2 ˆ ArH), 7.30 (d, J = 8.8 Hz,
1H, ArH), 6.46 (s, 2H, NH2), 5.69 (d, J = 6.4 Hz, 1H, H-1”), 5.38 (d, J = 6.4 Hz, 1H, OH), 5.09 (d,
J = 4.8 Hz, 1H, OH), 4.95 (dd, J = 6.0, 6.0 Hz, 1H, OH), 4.88–4.84 (m, 1H, H-2”), 4.24 (d, J = 13.8 Hz, 1H,
SCH), 4.19 (d, J = 13.8 Hz, 1H, SCH), 4.11–4.06 (m, 1H, H-3”), 3.81–3.78 (m, 1H, H-4”), 3.63–3.57 (m,
1H, H-5”), 3.50–3.43 (m, 1H, H-5”), 2.33 (s, 3H, CH3); 13C-NMR (DMSO-d6, 100 MHz) δ 160.31 (C=O),
155.64 (C=O), 153.25, 152.53, 151.08, 141.71, 140.95, 134.00, 132.61, 127.96, 124.08, 118.61, 117.38, 115.87,
88.29, 85.77, 70.60, 62.03, 32.65 (SCH2), 20.23 (CH3); IR (ATR) 3301 (br, OH + NH), 1720 (m, C=O), 1644
(s, C=O), 1566 (m), 1081 (s) cm´1; MS (FAB+) m/z 487 (M+, 1), 185 (9), 97 (31), 55 (100); HRMS (FAB)
calcd for (C21H21N5O7S)+: 487.1162, found: 487.1162.
5. Conclusions
Four new compound sets containing 20 imidazole–coumarin conjugates were established.
Experimental results indicate that five among the 20 conjugates significantly inhibited HCV
subgenomic replicon replication in the Huh 5-2 cell lines. In particular, the series of 1H-imidazole
conjugates (i.e., 3b, 3d, and 3e) exhibited the most appealing results, with EC50 values of 7.2, 5.1, and
8.4 µM together with SI values of 12, 15, and 21, respectively. The imidazole ring can be N-alkylated or
ribosylated as well as replaced by a benzimidazole, inosine, or guanosine. Nevertheless, the parent
imidazole conjugates with an N–H proton generally offers a higher SI value than those without such a
proton. Moreover, incorporation of substituents into the coumarin rings can increase both potency and
selectivity of the conjugates. These guidelines provide a valuable reference for medicinal scientists
attempting to optimize the anti-viral compounds during the drug development stage. The mechanism
of action of these conjugated compounds with significant activity towards viral enzymes will be studies
in due course.
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